Clinical Trial in a Dish for Space Radiation Countermeasure Discovery. (November 2022)

• Record Type: Journal Article
• Authors: Cao, Xu; Weil, Michael M.; Wu, Joseph C.
• Is Part Of: Life sciences in space research. Volume 35(2022)
• Page Start: 140
• Page End: 149
• Publication Date: 2022-11
• Subjects: Space radiation -- Human induced pluripotent stem cells -- Clinical trial in a dish -- Countermeasure discovery; Space biology -- Periodicals; 571.0919
• DOI: 10.1016/j.lssr.2022.05.006
• Languages: English
• ISSNs: 2214-5524

Abstract

Abstract: NASA aims to return humans to the moon within the next five years and to land humans on Mars in a few decades. Space radiation exposure represents a major challenge to astronauts' health during long-duration missions, as it is linked to increased risks of cancer, cardiovascular dysfunctions, central nervous system (CNS) impairment, and other negative outcomes. Characterization of radiation health effects and developing corresponding countermeasures are high priorities for the preparation of long duration space travel. Due to limitations of animal and cell models, the development of novel physiologically relevant radiation models is needed to better predict these individual risks and bridge gaps between preclinical testing and clinical trials in drug development. "Clinical Trial in a Dish" (CTiD) is now possible with the use of human induced pluripotent stem cells (hiPSCs), offering a powerful tool for drug safety or efficacy testing using patient-specific cell models. Here we review the development and applications of CTiD for space radiation biology and countermeasure studies, focusing on progress made in the past decade.